New chief medical officer at food allergy company Aimmune

23 June 2016
aimmune-large

Aimmune Therapeutics (Nasdaq: AIMT), a USA-based biopharma company developing treatments for life-threatening food allergies, has appointed Daniel Adelman its chief medical officer.

Dr Adelman is a renowned allergist and immunologist who spent seven years as chief medical officer at Alvine Pharmaceuticals, a privately-held US biotech focused on autoimmune and inflammatory diseases, particularly celiac disease.

He held the same role during five years at US pharma Sunesis Pharmaceuticals (Nasdaq: SNSS) and previously worked in various positions at Pharmacyclics and Genentech.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical